Central Asia Lumeichun Biotechnology (ZYLMD) Stock Statistics & Valuation Metrics

Central Asia Lumeichun Biotechnology has a market cap or net worth of $286.79K. The enterprise value is $485.42K.

Central Asia Lumeichun Biotechnology has 637,681 shares outstanding. The number of shares has decreased by -2.65% in one year.

Central Asia Lumeichun Biotechnology’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Central Asia Lumeichun Biotechnology is ―. Central Asia Lumeichun Biotechnology’s PEG ratio is -1.82.

In the last 12 months, Central Asia Lumeichun Biotechnology had revenue of ― and earned ― in profits. Earnings per share was ―.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

Central Asia Lumeichun Biotechnology pays an annual dividend of ―, resulting in a dividend yield of ―

Central Asia Lumeichun Biotechnology upcoming earnings date is ―, ―.

Central Asia Lumeichun Biotechnology as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Central Asia Lumeichun Biotechnology has paid ― in taxes.

Central Asia Lumeichun Biotechnology EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Central Asia Lumeichun Biotechnology has ― in cash and marketable securities with $10.55K in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Central Asia Lumeichun Biotechnology is ―, which is 11.43% higher than the current price. The consensus rating is ―